We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (SPORE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00584363
First Posted: January 2, 2008
Last Update Posted: October 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Charles Mel Wilcox, MD, University of Alabama at Birmingham
December 24, 2007
January 2, 2008
October 5, 2017
June 2004
September 2017   (Final data collection date for primary outcome measure)
To diagnose Pancreatic Cancer [ Time Frame: 5 years ]
Same as current
Complete list of historical versions of study NCT00584363 on ClinicalTrials.gov Archive Site
Preventing patient form being misdiagnosed [ Time Frame: 5 years ]
Same as current
Not Provided
Not Provided
 
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic Cancer)
The purpose of the study is to collect pancreatic tissue, blood and urine from adults to study pancreatic abnormalities.
The aim of the study is to standardize, collect and share pancreatic cancer related information, to be used for research purposes only by researchers from different participating institutions/centers.
Observational
Observational Model: Other
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:
Specimens are frozen and stored
Non-Probability Sample
Adults 19 years of age or older, pancreatic cancer patients at the University of Alabam at Birmingham.
Pancreatic Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
731
September 2017
September 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Person over 19 years of age, patient with a tissue-proven diagnosis of pancreatic cancer at the University of Alabama at Birmingham (UAB) University Hospital during the period, and cognitive ability to provide informed consent

Exclusion Criteria:

  • Person not 19 or older and have not had a tissue-proven diagnosis of pancreatic cancer.
Sexes Eligible for Study: All
19 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00584363
F040514008
2P50CA101955 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Charles Mel Wilcox, MD, University of Alabama at Birmingham
University of Alabama at Birmingham
National Cancer Institute (NCI)
Principal Investigator: Charles M Wilcox, MD University of Alabama at Birmingham
University of Alabama at Birmingham
October 2017